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Abstract
High prevalence of infection with high-risk human papilloma virus (HPV) ranging from 25 to 100% (average 31%) was
observed in breast cancer (BC) patients in Singapore using novel DNA chip technology. Early stage of BC demonstrated
higher HPV positivity, and BC positive for estrogen receptor (ER) showed significantly higher HPV infection rate. This unique
association of HPV with BC in vivo prompted us to investigate a possible involvement of HPV in early stages of breast
carcinogenesis. Using normal breast epithelial cells stably transfected with HPV-18, we showed apparent upregulation of
mRNA for the cytidine deaminase, APOBEC3B (A3B) which is reported to be a source of mutations in BC. HPV-induced A3B
overexpression caused significant cH2AX focus formation, and DNA breaks which were cancelled by shRNA to HPV18 E6, E7
and A3B. These results strongly suggest an active involvement of HPV in the early stage of BC carcinogenesis via A3B
induction.
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Introduction
Breast cancer (BC) is one of the major health issues faced by
women globally, ranking first in mortality (GLOBOCAN 2012:
Estimated Cancer Incidence, Mortality and Prevalence Worldwide
in 2012). Epidemiology gave the first hints for an involvement of
viral agents in specific human cancers [1]. Since the mid-20
th
century when mouse mammary tumor virus (MMTV) was
discovered to cause mammary cancers in mice, some viruses,
especially lately HPV, have been suspected to play an etiological
role in BC. A number of molecular epidemiological studies
conducted have accumulated data relating HPV to BC and
indicated that HPV DNA is present at a high frequency in BC
samples but is rare in normal breast tissues [2–8]. However, results
from these studies have been rather varied and sometimes
contradictory. Although some authors from these previous studies
suggested an etiological role for HPV in BC, no clear explanation
had been proffered for the causative mechanism other than the
high rate of HPV positivity as the sole reason with a precedent
premise that high-risk HPV has been established as a cause of CC.
On the other hand, other researchers held an opposing view of
these epidemiological results. For instance, Khan et al. concluded
that it is unlikely for integrated HPV to be etiologically involved in
the development of BC since the viral load was very low (a
geometric mean of 5.4 copies per 10
4 cells) [2]. Many recent
reports also showed that HPV genome could be detected in non-
genital cancers such as head and neck (oesophageal, laryngeal and
tonsil), lung, urothelial, breast and colorectal cancers [9,10].
HPV is a DNA virus with a circular double stranded
configuration, with more than 100 subtypes found to date
[11,12]. Most of the known HPV types cause no symptoms in
general, although some types can cause warts, while others are
believed to lead to cervical cancer [13] and other forms of genital
cancers (vulvar, vaginal, anal, and penile) [14]. The HPV genome
is composed of 8 genes (E1, E2, E4, E5, E6, E7, L1 and L2) and a
long control region (LCR) which has promoter and replication
origin for replication [15]. In the pre-cancerous lesions of cervical
cancer, most HPV genomes persist in an episomal state whereas in
many high-grade lesions, these viral genomes are found integrated
into the host chromosome. Amongst various types of HPVs, 15
types including HPV-16 and HPV-18 are categorized as high-risk
oncogenic HPVs based on the fact that they account for over 90%
of cervical cancer [16]. E7 protein of high-risk HPVs has a high
affinity to human retinoblastoma (Rb) proteins, and this leads to
enhanced pRb degradation, resulting in the activation of E2F
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[17,18]. The binding of Rb with E7 leads to inhibition of cell
apoptosis through tumor suppressor p53-dependent pathway.
Therefore, to overcome apoptosis by p53, HPV exploits another
important oncogene product, E6 protein, which can bind p53 for
degradation, leading to prevention of cell growth inhibition. E6
and E7 proteins have complementary function and this synergistic
effect can efficiently lead to cell cycle progression, anti-apoptotic
effect and genomic instability that cause accumulation of cellular
mutations over time, and consequent tumor initiation, transfor-
mation and progression to cancer [19].
Hosts have means such as innate and adaptive immunities to
combat against invasion by various pathogens including bacteria
and viruses. Innate immunity is a first guardian, which induces
interferon resulting in activation of IFN-stimulated genes (ISGs)
[20]. In fact, the APOBEC3 family of cytidine deaminases, which
are IFN-inducible, play a key role in the innate immune system
against various exogenous viruses as well as endogenous retroviral
elements [20]. APOBEC3 enzymes can edit DNA and/or RNA
sequences [21–23]. However, further studies have revealed that
inappropriate expression of APOBEC subgroup seems to act as a
genomic mutator that eventually causes cancer [24–28]. Indeed,
overexpression of other cytidine deaminases, APOBEC1 and
activation-induced deaminase (AID) can cause hepatocellular
carcinoma and T cell lymphomas in transgenic mice, respectively.
Also, several other studies have disclosed expression of AID gene
transcripts or proteins in gastric cancer [29] and human lymphoid
malignancies [30,31]. Very recently, A3B has been implicated by
several groups independently as a source of mutations in various
cancers including breast, bladder, lung, head and neck, and
cervical cancers [25–28]. It is an indisputable fact that HPV
infection is a major risk factor for the development of cervical and
head and neck cancers in which the A3B mutation signature is
found to be enriched. Here, our aim was to probe whether HPV
could be the initiator of breast carcinogenesis through A3B
overexpression which leads to excessive mutations, dysregulated
cell cycle and subsequent transformation, and thus provide the
missing link in the study of the role of HPV in BC causation. We
hypothesize that HPV could trigger aberrant expression of A3B in
breast epithelial cells which results in genomic instability. We first
studied the prevalence of HPV in breast cancer tissue samples
from patients, and subsequently tested our hypothesis of HPV’s
role in breast carcinogenesis in an in vitro system.
Methods
DNA Samples
More than 210 fresh frozen breast tumor specimens were
obtained from the National University Health System (NUHS)
Tissue Repository (TR) with approval from the Institutional
Review Board (IRB) at the National University of Singapore
(NUS) and NUHS. The specimens were collected from surgical
operations in the National University Hospital (NUS) and banked
in the NUHS TR.
Genomic DNA (gDNA) was extracted from all above-men-
tioned BC samples by use of the QIAGEN DNeasy Blood &
Tissue Kit (Venlo, Netherlands) and stored at 220uC before use.
After extraction, specimens were subjected to DNA microarray
array (TOSHIBA, Tokyo, Japan) for the detection of 13 high-risk
HPV genomes, according to manufacturer’s instructions.
HPV Detection Using TOSHIBA Microarray
HPV detection using the TOSHIBA DNA chip was performed
according to manufacturer’s instructions [32]. Briefly, 200–500ng
of gDNA were denatured at 95uC for 5 min, and then added into
each of the 6 loop-mediated isothermal amplification (LAMP)
reaction tubes. The LAMP reaction, which amplifies the HPV
genome by targeting the L1 region of 13 high-risk HPV subtypes
(16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68), performed at
the following conditions: 65uC for 90 min then 80uC for 5 min.
Thereafter, samples from the 6 reaction tubes were collected into
one tube, prior to the addition of hybridization buffer and
application to the electrochemical DNA chip, which contains
specific DNA probes for the L1 region of 13 high-risk HPVs.
Hybridization and detection of HPVs were performed by the
Genelyzer (TOSHIBA, Tokyo, Japan).
Constructs
APOBEC3B-promoter (A3B-Pro) was amplified using genomic
DNA and specific primers as follows: 59-ACGGGGTACCGTCT-
TATCCTTTGTCCATCTCTTTCTGAC-39,5 9-ACGGGG-
TACCGTCTTATCCTTTGTCCATCTCTTTCTGAC-39, and
cloned into pGL3 vector (Promega). pUC-HPV16 and pSP-
HPV18 plasmids were constructed as described previously [33].
Oligonucleotides for gene specific short-hairpin RNA for APO-
BEC3B, HPV18-E6 and HPV18-E7 (Table S1) were ordered from
Integrated DNA Technologies and cloned into pSuperRetro
vector (OligoEngine, WA).
Cells
293T and MCF10-A cells were obtained from American type
tissue culture (ATCC, VA). 293T cells were maintained in 10%
FBS supplemented DMEM. MCF10A cells were cultured with 5%
horse serum (Lifetech), 20ng/ml rEGF, 100ng/ml Cholera Toxin,
0.5 mg/ml hydrocortisone (SIGMA, MO) and rInsulin (Roche,
Upper Bavaria, Germany).
Stably HPV18 infected MCF10-A (MCF10A-HPV18) cells
were established by transfection of linear pSP-HPV18 cut by
EcoRI followed by limiting dilution at 7 days after transfection to
obtain HPV18 infected cells, in which integration of HPV18
genome was confirmed using Alu-PCR.
Reagents
Anti-HPV18 E7 (8E2) and anti-Flag M2 antibodies were
purchased from Abcam (Cambridge, UK) and SIGMA respec-
tively. Anti-cH2AX, cH2AX-Alexa647, b-actin, mouse IgG-HRP
and rabbit IgG-HRP antibodies were purchased from Cell
Signaling technology.
Luciferase Assay
Circular or linear HPV plasmid was transfected into 293T and
MCF10-A cells with A3B-Pro and TK-Rluc as control. Cells were
harvested at 48–72 hrs post-transfection followed by lysis.
Luminescence was measured using Dula-Luciserase kit (Promega,
WI) and Synergy H1 hybrid Multi-Mode Microplate reader
(BioTek, VT).
RNA Isolation, cDNA Synthesis and qRT–PCR
Patients RNA samples were obtained from the National
University Health System (NUHS) Tissue Repository (TR) with
approval from the Institutional Review Board (IRB) at the
National University of Singapore (NUS) and NUHS. Total
RNA from various MCF10-A cells was extracted using RNA easy
kit (QIAGEN). Reverse transcription was performed using Go-
script reverse transcription system (Promega) after DNase I
treatment (Turbo DNA free kit, Lifetech). Quantification of
High-Risk HPV and APOBEC3B in Breast Cancer
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(Bio-rad, CA) and gene specific primers (Table S1).
Immunofluorescence
MCF10-A and MCF10A-HPV18 cells were fixed by 4%
paraformaldehyde/PBS following washing cells with PBS. Cells
were treated with PBS containing 4% normal goat serum
(Lifetech), 0.5% Triton-X 100 (SIGMA). E7 or cH2AX proteins
were stained by anti-HPV18 E7 (8E2) and anti-mouse IgG-
Alexa568 Ab or cH2AX-Alexa647 (CST) followed by DAPI
staining. After mounting slides using ProLong Gold Antifade
Reagent (Lifetech), cells were observed using Olympus X81
immunofluorescent microscope (Tokyo, Japan).
Stable A3B, HPVE6 or E7 Knockdown MCF10A Cells
The pSR-shRNA plasmid was transfected with pVSVG plasmid
into Plat-E cells and then supernatants were collected at 60 hrs
post-transfection after filtration by 0.45 mM syringe-top filter. Cells
were infected with retrovirus vectors for 12hrs in presence of
polybrene (SIGMA) followed by puromycin (Invivogen, CA)
selection (4 mg/ml) for 48hrs. Cells were cultured in presence of
2 mg/ml of puromycin before use. Knockdown of target genes
were checked by qRT-PCR as mentioned above.
Comet Assay
Microscope slides were coated with 1.5% agarose and dried.
Low-melting agarose (0.5% in PBS) was combined 1:1 with
MCF10-A and MCF10A-HPV18 cells. Seven-thousand cells were
added to coated slides and the cells were lysed overnight in 10mM
Tris, 100mM EDTA, 2.5M NaCl, 10%DMSO and 1% Triton X-
100 (pH10). Slides were incubated for 20 min in chilled running
buffer (300mM NaOH, 1mM EDTA, pH13) then run at 25V for
25 min at 4uC. Gels were neutralized with 400mM Tris-HCl,
pH7.5 followed by propidium iodide staining for 1hr. The
microgels were allowed to dry and comets were observed by
microscope. The % DNA in tail was calculated by Tail DNA
intensity/(Head DNA intensity+Tail DNA intensity) 6100.
Statistical Analysis
Data were analyzed using STATA (version 11.0, Stata
Corporation, College Station, TX, USA). Associations between
HPV status and various breast cancer parameters and risk factors
were tested using either Fisher’s exact test or the Chi-squared test
for trend. The tests were all two-sided, and statistical significance
was defined as p#0.05.
Results
BC Tissues with Estrogen Receptor (ER) Showed
Significantly Higher HPV Prevalence than ER-negative
Tumors
We first examined the relationship between HPV status, and
pathological and demographic features in 209 female BC cases in
Singapore using the DNA chip system and genomic DNA
extracted from frozen samples (Figure. 1, Table 1). High-risk
HPV DNA was detected in 31% of all BC samples. Association of
BC with HPV seemed to depend on age, histological types, and
stages of malignancy with the prevalence ranging from about 20%
to nearly 100% (Fig. 1 and Table 1). For instance, the prevalence
of HPV varied greatly depending on pathological features whereby
almost all lobular carcinoma (LC) type of BC cases were positive
for HPV even though the numbers were small for both LC in situ
(IS) (LCIS) and invasive LC (ILC) (p=0.0003) while that of IDC
was lower than 30%. The HPV positivity was lower when the
patients were younger, but it seemed to increase with age (p for
trend=0.1155). Irrespective of ethnicity, all 3 major groups
(Chinese, Malay and Indian) showed essentially a similar HPV
prevalence. The patients with a family history of BC and BC at
both sides of the breast seemed to show higher HPV positivity
suggesting the infectious origin of some types of BC, especially due
to high-risk HPVs (Table 1). Importantly, BC cases which are ER-
positive showed significantly higher HPV prevalence than ER-
negative tumors (p=0.0378) (Table 1).
Majority of HPV types found in BC were HPV-16 (47%) and
HPV-18 (36%) followed by HPV-35, -56, -59 and -31 subtypes
(See Figure S1). We also checked the copy number of HPV in our
BC samples using HPV-16 or -18 L1 gene specific quantitative-
PCR. As shown in Table S2, most of the cervical cancer samples
used as controls had more than 1 copy/cell of HPV-16 or HPV-
18 genome, whereas all BC samples at various stages of cancer
harbored viral copy numbers at much lower level than 1 copy/cell
as reported in previous studies.
HPV-positive BC Showed Better Prognosis than Virus-
negative Tumors
HPV-positive tumors showed significantly longer duration
period for recurrence after BC resection as compared to virus-
negative tumors (p=0.047) (Fig. 2a). When the same analysis was
performed among ER-positive cases exclusively, again HPV-
positive tumors showed a longer duration until recurrence as
compared to HPV–negative tumors although this was not
statistically significant (p=0.135) (Fig. 2b). Irrespective of HPV
status, ER-positive cases apparently showed a longer duration than
ER-negative cases. Pre-malignant BCs such as atypical ductal
hyperplasia, ductal carcinoma in situ (DCIS) and LCIS highly
express ER, and none, low or modest ER-expressing cells are
detected in invasive breast carcinoma (IBC) [34], suggesting a
possibility that ER-positive BC seems to be at early stage of cancer.
HPV Induces A3B Expression in Normal Breast Cells
To address whether viral infections could trigger A3B induction
and cause mutagenesis of host genomes, we transfected A3B
reporter construct together with HPV in either the complete
Figure 1. Relationship between HPV status and patholological
features. Numbers at the bottom of each bar represent (number of
HPV-positives)/(total sample numbers). Difference of HPV prevalence
between invasive ductal carcinoma (IDC) and invasive LC (ILC) was
statistically significant (p=0.0003). IS; in situ.
doi:10.1371/journal.pone.0097787.g001
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HPV-positive HPV-negative Total p-value
N(%) N(%) N(%)
Age
,40 1(6.7) 14(93.3) 15
40–49 12(23.5) 39(76.5) 51
50–59 17(25.8) 49(74.2) 66 *0.1155
60–69 14(31.8) 30 (68.2) 44
.70 8(30.8) 18(69.2) 26
Total 52(25.7) 150(74.3) 202 (100)
Ethnicity
Chinese 32(30.8) 72(69.2) 104
Malay 11(22.4) 38(77.6) 49
Indian 6(26.1) 17(73.9) 23 **0.445
Others 4(16.7) 20(83.3) 24
Total 53(26.5) 147(73.5) 200(100)
Family history
Yes 7(29.2) 17(70.8) 24
No 35(25.9) 100(74.1) 135 ***0.8026
Unknown 1(6.7) 14(93.3) 15
Total 43(24.7) 131(75.3) 174(100)
BC at both sides
Yes 4(36.4) 7(63.6) 11
No 42(25.9) 120(74.1) 162 ***0.4857
Unknown 0(0.0) 1(100) 1
Total 46(26.4) 128(73.6) 174(100)
Estrogen Receptor
Positive 35(29.8) 83(70.3) 118
Negative 8(14.5) 47(85.5) 55 $0.0378
Unknown 0(0.0) 1(100) 1
Total 43(24.7) 131(75.3) 174(100)
Progesterone Receptor
Positive 30(26.8) 82(73.3) 112
Negative 13(21.3) 61(78.7) 61 $0.466
Unknown 0(0.0) 1(100) 1
Total 43(24.7) 131(75.3) 174(100)
HER2
Positive 7(19.4) 29(80.6) 36
Negative 23(28.8) 57(71.2) 80 $0.3626
Unknown or N/A 13(22.4) 45(77.6) 58
Total 43(24.7) 131(75.3) 174(100)
Vascular invasion
Present 19(28.8) 47(71.2) 66
Absent 24(24.0) 76(76.0) 100 $$0.5875
ND 0(0.0) 8(100) 8
Total 43(24.7) 131(75.3) 174(100)
Lymph vessel invasion
Present 19(29.2) 46(66.7) 65
Absent 24(24.0) 76(76.0) 100 $$0.4727
ND 0(0.0) 9(100) 9
Total 43(26.4) 131(69.7) 174(100)
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fragments (as a representation of integrated HPV genome; Fig. 3a)
of HPV genomes into 293T cells. Results showed that transfection
of circular HPV genome could activate A3B promoter (Fig. 3b).
Similarly, cells transfected with fragmented HPV genome showed
higher promoter activity than circular HPV genome (Fig. 3c),
indicating that E6 and E7 are most likely responsible genes to
activate A3B promoter. We also performed the similar experi-
ments with normal breast derived cells, MCF10-A upon transfec-
tion with reporter plasmid and fragments of HPV-16 or HPV-18
genome. As shown in Fig. 3d, A3B promoter was strongly
activated in MCF10-A cells transfected with HPV genome. Next,
we established the MCF10-A cells persistently infected with HPV-
18 to see whether A3B gene is consistently activated by HPV
infection. HPV-positive cells expressed mRNA for A3B at about
2.5 times more than parental cells calculated based on normalized
A3B/GAPDH ratio (Fig. 3e). Interestingly, expression of other
cytidine deaminase family genes was in general suppressed
(Fig. 3e), suggesting that activation of A3B by HPV seems to be
specific.
The results that fragments of HPV18 digested with EcoRI could
still activate A3B promoter (Fig. 3a, c and d), and only E6 and E7
intact genes are expressed in persistently HPV18 infected MCF10-
A cells (Fig. 3f and g) (although N-terminal of E1 gene is also
expressed), suggest that E6 and E7 genes are essential factors to
induce A3B expression. Next, 293T cells were transfected with E6
or E7 expression plasmid together with reporter genes to address
whether these viral oncogenes were responsible for A3B induction.
The results showed that though weakly but still significantly, both
E6 and E7 were able to induce A3B expression (Fig. S2), indicating
that E6 and E7 are responsible in upregulating A3B expression.
These results show that HPV infection in breast cells can
specifically activate A3B and its induction seems to be coopera-
tively regulated by E6 and E7.
HPV-dependent A3B Activation Triggers Genomic
Instability in MCF 10-A Cells
Phosphorylated-Histone 2AX (known as cH2AX), which is
widely known as a marker of DNA damage for cancerous
phenotype, was significantly increased in MCF10-A persistently
infected with HPV18 compared to mock infected cells as revealed
by immuno-staining (Fig. 4a) and Western blotting (Fig. 4b). With
Table 1. Cont.
HPV-positive HPV-negative Total p-value
N(%) N(%) N(%)
Lymph node metastasis
Low (1–29%) 15(28.3) 38(71.7) 53
10.2006
Mid (30–59%) 5(26.3) 14(73.7) 19
High (.60%) 7(28.0) 18(72.0) 25
20.5199
Total (1–100%) 27(27.8) 70(72.2) 97
No metastasis 13(18.3) 58(81.7) 71
30.3906
Unknown or N/A 1(33.3) 2(66.7) 3
Total 41(24.0) 130(76.0) 171(100)
40.1993
*Trend test, **Fisher: Chinese v.s. Indian, ***Fisher: Yes v.s. No,
$Fisher: Positive v.s. Negative,
$$Fisher: Present v.s. Absent,
1Fisher: Meta Low v.s. No meta,
2Fisher: meta Mid v.s. No meta,
3Fisher: Meta high v.s. No meta,
4Fisher: Meta total v.s. No meta.
doi:10.1371/journal.pone.0097787.t001
Figure 2. Significant difference of duration until recurrence
between HPV-positive and -negative tumors. Fifty BC samples of
the patients from whom information were available were compared
between HPV-positive and -negative groups (a), and ER/HPV-double
positive, ER-single positive, HPV single positive and ER/HPV-double
negative groups (b). Numbers in brackets indicate total number of
samples for each case, respectively. Student’s t-test was performed,
with p-values indicated on the graph.
doi:10.1371/journal.pone.0097787.g002
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PLOS ONE | www.plosone.org 5 May 2014 | Volume 9 | Issue 5 | e97787Figure 3. Induction of APOBEC3B by HPV in the normal breast, MCF10-A cells. (a) HPV16 and HPV18 genome structure, and restriction
enzyme site position on HPV genome. (b and c) APOBEC3B (A3B) promoter activity. The circular indicated plasmids (b) or same copy number of
indicated plasmids digested by restriction enzymes (c) were transfected with A3B-Promoter-luciferase and TK-RLuc into 293T followed by detection of
luciferase activity at 48hrs post-transfection. Fold A3B-luciferase activity was normalized by TK-Rluc value. (d) A3B promoter activity at 72hrs in
MCF10-A cells as same experiment with panel b and c. (e) Indicated cystidine deaminases mRNA level in MCF10-A and stably HPV18 infected cells.
Cells were lysed to extract total RNA, and these RNAs were subjected to quantitative RT-PCR (qRT-PCR). The fold induction of was calculated after
normalization by GAPDH mRNA level. (f) RT-PCR for E6, E7, E1 E2 and E5 gene. Cells were lysed to extract total RNA, and its RNA was subjected to
conventional RT-PCR. (g) E7 expression in MCF10A-HPV18 cells. Cells were fixed by paraformaldehyde followed by staining of E7 protein and nuclear
using anti-HPV18 E7 Ab and DAPI respectively. Values represent the mean 6 SD of at least three independent experiments. Student’s t-test was
performed, with p-values indicated on the graph.
doi:10.1371/journal.pone.0097787.g003
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were apparently and strongly induced in persistently HPV18
infected MCF10A cells by the comet assay (Fig. 4c and d). These
results indicate that A3B activation through HPV infection seems
to induce genomic instability and DNA breaks to initiate tumor.
Knockdown of A3B, E6 and E7 Abrogated HPV-induced
Genomic Instability
We next conducted knockdown experiments for A3B, E6 and
E7 using gene specific shRNA to address our hypothesis. Various
A3B-specific shRNAs could decrease A3B expression (Fig. 5a), and
the silencing of A3B alone abrogated cH2AX induction (Fig. 5b).
Both shRNA for E6 and E7 could simultaneously decrease E6 and
E7 expression due to transcription of E6 and E7 genes from the
same mRNA (Fig. 5c and d), and reduction of E6 and E7
expression resulted in suppression of cH2AX induction (Fig. 5e).
More importantly, silencing of E6 and E7 also cancelled A3B
induction (Fig. 5a), indicating that A3B is apparently activated
through HPV18 E6 and E7, and its activation renders cells
cancerous as evidenced by genomic instability condition. Howev-
er, knockdown of E6 and E7 still showed significant further
reduction of cH2AX even in stable A3B-knockdown MCF10A-
HPV18 cells, in which more than 85–90% of A3B expression were
suppressed (Fig. S3). These results suggest that DNA damage and
Figure 4. A3B activation by HPV infection increases genome instability. (a) cH2AX immunofluorescence. Cells were fixed by 4%
paraformaldehyde followed by staining of cH2AX protein and nuclear using anti- cH2AX Ab and DAPI respectively. (b) cH2AX western blot. Cells were
lysed and subjected to western blot. The cH2AX and b-actin were detected using anti- cH2AX and b-actin Ab. (c) Comet assay. Cells were seeded
onto agarose-coated slide glass after mixing with 1.5% agarose followed by lysis. Slides were subjected to electrophoresis and then genomic DNA
was stained by PI. (d) Statistical analysis for panel C. Student’s t-test was performed, with p-values indicated on the graph.
doi:10.1371/journal.pone.0097787.g004
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HPV18 E6/E7-A3B (A3B-dependent) and 2) HPVE6/E7 direct
(A3B-independent) pathway (Fig. S4).
HPV Infection and A3B Upregulation Seem to be
Correlated in BC Patients’ Samples
Finally, we checked whether A3B upregulation is associated
with HPV infection using BC samples from patients. According to
results from Fig. 1 and table 1, HPV-negative (n=11) and -
positive (n=12) BC were randomly selected, and then A3B and
A3G mRNA level were monitored. As shown in Fig. 6 a and b,
result showed tendency that A3B expression level seems to be
correlated with HPV infection although statistical significance
could not be obtained. In contrast, there was no correlation at all
between A3G and HPV status consistent with a previous report
showing that there is no association between A3G expression and
BC [25]. Taken together, our results implicate that A3B, which is
reported to be a specific source of mutation in BC, is actually
induced by HPV infection, suggesting that HPV is likely to be one
of the initiators for at least a certain portion of BCs.
Discussion
To address whether HPV is directly involved in carcinogenesis
of BC, we first conducted a molecular epidemiological analysis
using patients’ samples. Our results showed the evidence of high-
risk HPVs infection in BC patients unambiguously among the
different ethnic populations (Table 1). A possible preponderance of
lobular histological types (LC) with HPV infection was noted.
Most prevalent subtypes were HPV-16 and -18, and other types of
HPV such as HPV-35, -56, -59 and -31 followed by other minor
subtypes.
Our data showed that tumor cells with ER significantly
correlated with high HPV infection (Table 1). The observation
raises very intriguing possibilities that 1) estrogen can directly
affect transcription of HPV E6/E7 oncogenes in BC system, and
2) ER-positive normal cells could be an initial target of HPVs
Figure 5. Abrogation of HPV-induced cancer phenotypes by shRNA against HPV E6, E7 and A3B. (a) A3B mRNA level in stable A3B, E6 or
E7-knockdown MCF10A-HPV18 cells. A3B, E6 or E7 stably knocked down cells were established using shRNA retroviral vector. Total RNA was extracted
from cells and then subjected to qRT-PCR. (b) cH2AX level in stable A3B-knockdown MCF10A-HPV18 cells. Cells were lysed after selection using
puromycin and then subjected to western blot. The cH2AX and b-actin were detected using anti-cH2AX and b-actin Ab. The number at bottom of
panel shows band intensity ratio after normalized by b-actin level. (c and d) HPV-18 E6 or E7 mRNA level in stable E6 or E7-knockdown MCF10A-
HPV18 cells. Total RNA was extracted and then subjected to qRT-PCR. (e) cH2AX level in stable HPV18 E6 or E7-knockdown MCF10A- HPV18 cells.
Cells were lysed after selection using puromycin, and then subjected to western blot. The cH2AX and b-actin were detected using anti-cH2AX and b-
actin Ab. The number at bottom of panel shows band intensity ratio after normalization by b-actin level. Values represent the mean 6 SD of at least
three independent experiments. Student’s t-test was performed, with p-values indicated on the graph.
doi:10.1371/journal.pone.0097787.g005
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S4). A study in murine model of cervical cancer suggested that
HPV infection alone is not sufficient to lead to cervical
carcinogenesis, and that estrogen is required [35]. Moreover, the
synergy between estrogen and p53 insufficiency by E6 protein is
important for carcinogenesis of cervical and breast cancer in mice
model [36]. In addition, HPV-positive and ER/HPV-positive BCs
show longer duration until recurrence than others (Fig. 2).
Etiological study reports that pre-malignant BCs highly express
ER [34], indicating that ER-positive BCs represent early stage of
cancer compared to ER-negative BCs. Therefore, it is quite
reasonable that ER-positive BCs tend to show better prognosis
even if the advantage that chemotherapy is available for ER-
positive BCs is not considered. Collectively, these data indicate
that HPV may have some role in the early stage of BCs, and
suggest the relationship between estrogen and HPV E6/E7-
dependent BC initiation.
We confirmed several past reports showing that HPV, especially
high-risk HPV, was detected from the samples of BC in vivo. Our
data is also consistent with those from previous studies by Khan
et al. which found that HPV load is very low in BC samples, being
far lower than 1 copy/cell [2] (Table S2). However, it is well
known that some infectious agents (e.g. Helicobacter pylori for
gastric cancer and hepatitis viruses for hepatocellular carcinoma)
act as indirect carcinogens, without persistence of their genes
within the respective cancer cells [1]. Even in HPV, some
cutaneous types are attributed as indirect carcinogens [1]. Another
important fact to support HPV as possible cause of BC is high-risk
HPV E6 and E7 are used as the most efficient and reproducible
model for human mammary epithelial carcinogenesis in vitro.
These data prompted us to test an intriguing possibility that HPV
might act predominantly at earlier but not so significantly at later
steps of breast carcinogenesis. HPV E6 and E7 proteins are
oncogenic per se and their synergistic effects can efficiently lead to
cell cycle progression, anti-apoptotic effect and genomic instability.
Indeed, previous reports have demonstrated that HPV can induce
cH2AX and DNA breaks [19,37]. During our investigations
seeking for possible DNA mutators in the host inducible by HPV,
we encountered striking data suggesting a model in which A3B-
catalysed deamination provides a chronic source of DNA damage
in BC that could mutate TP53 [25]. Simultaneously, several
groups independently reported using a novel analytical approach
that A3B is a likely source of mutations in most major human
cancers including breast carcinoma, bladder, lung, cervical, and
head and neck cancers [26,38]. Importantly, HPV is attributed as
a cause of the latter 2 types of cancers. Thus, we investigated the
relationship between A3B mutagenesis and HPV infection in
breast cells. Our results clearly show that HPV infection induces
overexpression of A3B (Fig. 3) and infected cells represent more
malignant phenotype than parental cells (Fig. 4). These malignant
phenotypes were largely abrogated when A3B was knocked down
in HPV-infected cells (Fig. 5). Hence, it is indicated that HPV
effect is exerted mainly through induction of this enzyme and is
more indirect in BC oncogenesis.
We found a positive correlation between A3B expression and
HPV infection even in primary BC samples (Fig. 6) although the
Figure 6. Correlation of A3B expression level and HPV infection in BC patients. Total RNA from BC patients were obtained from NUHS TR.
Samples were subjected to quantitative RT-PCR (qRT-PCR). The data of A3B (a) and A3G (b) were shown after normalization by GAPDH mRNA level.
The number at the bottom of graph indicates the number of patients. Patient 1–11 are HPV-negative, patient 12–23 are HPV-positive.
doi:10.1371/journal.pone.0097787.g006
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to the small sample numbers. In this regard, it is notable that EBV,
which shares many similarities with HPV, is also reported to be
highly associated with BC in vivo epidemiologically [7,39]. Our
preliminary studies indicate that EBV can induce a wider range of
AID/APOBEC family proteins more efficiently than HPV (Ohba,
unpublished results). It is thus possible that high expression of A3B
seen in HPV-negative samples is caused by other viruses such as
EBV. The experiments seeking for possible involvement of EBV in
BC and to inquire whether HPV-infected cells that express high
levels of A3B show more mutations than uninfected parental cells
are underway. All these data support our contention that HPV
plays an important role mainly at initial step of breast
carcinogenesis whereas the same virus seems to play the role in
both initiation and maintenance in CC oncogenesis. Once the cells
undergo critical mutation at certain host genes initially, persistent
effect of A3B and its inducing agent HPV are no longer required
given the mutator role of A3B, or their continued presence in the
tissue possibly is selected against. Therefore, proof that DNA
deaminases induce human cancer is at best indirect [40].
It has been suggested for a long time that inflammation and
cancer share some basic mechanisms [41]. Especially, an
important aspect to be considered is based on the fact that A3B
is the product of one of the interferon-inducible genes (ISG) [20–
23]. Accidental induction of deaminases can result in mutations in
key target genes such as tumor suppressors and oncogenes. It is
reported that estrogen and inflammatory cytokines, such as
interferon, interleukin-6, and tumor necrosis factor can induce
AID/APOBEC ptoteins through NF-kB [40,42–46]. As such,
would there be an absolute requirement for HPV specifically as
compared to other infectious agents in BC carcinogenesis? As
compared to most other conventional viruses, HPV (and some
other concogenic viruses) is apparently unique in its ubiquitousness
and oncogenicity with viral oncogenes. A more important feature
of human oncogenic viruses is their modest replicative ability so
that their cytotoxicity and interferon inducing ability are relatively
weak. This rather modest ability to induce AID/APOBEC family
protein of HPV in cells may well explain long latency and
requirement of additional factors in generation of human cancer
including BC. If this assumption is correct, it is also important to
address a possible involvement of EBV or its synergy with HPV in
BC carcinogenesis because of its high epidemiological association
with BC in vivo [7,39]. In this context, some BC-related clinical
conditions such as inflammatory BC definitely require similar
studies on possibility of the involvement of infectious agents
including HPV, EBV and other microbes, too.
In present study, we showed that HPV seems to be possible
initiator for BCs development through A3B activation leading to
genomic instability. However, there are still several pathways for
induction of genomic instability and tumor initiation. Among these
pathways, oxidative stress (OS) including reactive oxygen species
(ROS) is one of the sources to induce DNA damage including
DNA double-strand breaks causing cancer initiation [47–49].
Some infectious agents such as hepatitis B, C and helicobacter
pylori can indeed induce OS during infection [47,50]. Recently,
some reports attempted to show the involvement of OS in HPV-
dependent carcinogenesis [51–53]. However, the role of OS in
HPV infection is still unclear, especially in tumor initiation step.
There are various possibilities that A3B and OS act independently,
concomitantly, cooperatively or even synergistically to induce
tumor initiation during HPV infection. Further analysis is required
to elucidate whole tumor initiation mechanism by HPV.
In conclusion, we propose here a provocative carcinogenic
mechanism of BC that aberrant A3B expression caused by HPV
infection might be a mechanism of mutation accumulation in the
breast epithelium during HPV-associated breast carcinogenesis
which possibly occurs in the early stage of multi-step, multi-
factorial carcinogenesis. Recent genome-wide analysis results on
broad-spectrum cancer also show the relevance of our contention
[27,28]. If this model turns out to be at all feasible, reevaluation of
several other HPV-associated non-genital cancer systems such as
those in lung, colon, bladder, and so on is warranted since these
tumors represent a significant reminiscence to BC in terms of high
infection rate but low copy numbers of high-risk HPV in cancer
tissue [9]. Moreover, the same idea could be applied even to the
other types of human cancers induced by other oncogenic DNA
viruses such as EBV and human polyomaviruses, the roles of
which are poorly appreciated so far. Eventually, the role of HPV
in development of BC and other HPV-associated non-genital
cancers will be ascertained by monitoring the effect on the disease
prevalence in women by cervical cancer vaccinations against high-
risk HPV types in comparison to women who had not been
vaccinated.
Supporting Information
Rluc value. Values represent the mean 6 SD of three independent
experiments. (c) Dose-dependent expression of Flag-E7. Cells were
lysed, and then subjected to western blot. The Flag-E7 and b-actin
were detected using anti-Flag M2 and b-actin Ab.
(TIF)
(TIF)
High-Risk HPV and APOBEC3B in Breast Cancer
PLOS ONE | www.plosone.org 10 May 2014 | Volume 9 | Issue 5 | e97787
Figure S1 HPV genotypes analysis in BC tissues. Thirteen
high-risk HPVs (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and
68) in derived from fresh BC tissues were detected in gDNAs
using theTOSHIBA DNA chip. Percentage of HPV types were
analysedwith HPV positive samples (n=217).
(TIF)
Figure S3 Additional cH2AX reduction by shHPV18 E6 or E7
in stable A3B-knockdown MCF10A-HPV18 cells. The cH2AX
level in A3B and HPV18 E6 or E7-knockdown MCF10A-HPV18
cells. Stable A3B-knockdown MCF10A-HPV18 cells were trans-
fected with HPV18 E6 or E7 shRNA plasmid. Cells were lysed at
72 hrs after transfection, and then subjected to western blot. The
cH2AX and b-actin were detected using anti-cH2AX and b-actin
Ab. The number at bottom of panel shows band intensity ratio
after normalization by b-actin level.
Figure S4 Possible BC initiation mechanism by HPV. The
overall possible scheme of BC initiation mechanism by HPV.
1) HPV is infected to cells, replicates viral proteins and genome
and then produces progeny viruses. 2) Estrogen receptor
augments HPV replication. 3) A3B production is induced by
E6 and E7 proteins derived from HPV episome or integrated
genome thatresults in persistent HPV infection. 4) Induced A3B
by E6/E7 and E6/E7 proteins themselves augment genomic
instability such asDNA breaks resulting in cH2AX activation. 5)
Genomic instability accumulates mutation in host genome and
renders cells cancerous. 6) Simultaneously, E6/E7 interfere
p53/Rb function respectively to prevent apoptosis and promote
cell cycle progression. 7) Those molecular mechanisms
cooperatively generate tumor.
(TIF)
Figure S2 Dose-dependent APOBEC3B promoter activation by
HPVE6 and E7. (a and b) APOBEC3B (A3B) promoter activity.
The indicated dose of E6 (b) and Flag-E7 (c) plasmids were
transfected with A3B-Promoter-luciferase and TK-RLuc into
293T followed by detection of luciferase activity at 48hrs post-
transfection. Fold A3B-luciferase activity was normalized by TK-Text S1 Supporting information text describes materials and
methods for all of supporting figures and tables.
(DOC)
Acknowledgments
We thank Harald zur Hausen, Heidelberg for his critical and invaluable
comments throughout our studies and Tadahito Kanda, RIKEN, Japan for
giving us the HPV constructs. We are also grateful to Toshifumi
Matsuyama (Nagasaki University) and to other members of the laboratory
for helpful discussions.
Author Contributions
Conceived and designed the experiments: NY KO. Performed the
experiments: KO MY QW. Analyzed the data: KO KI MY NG MN
PC RY JELW. Contributed reagents/materials/analysis tools: SM. Wrote
the paper: NY KO PC.
References
1. zur Hausen H (2009) The search for infectious causes of human cancers: where
and why (Nobel lecture). Angew Chem Int Ed Engl 48: 5798–5808.
2. Khan NA, Castillo A, Koriyama C, Kijima Y, Umekita Y, et al. (2008) Human
papillomavirus detected in female breast carcinomas in Japan. Br J Cancer 99:
408–414.
3. Kroupis C, Markou A, Vourlidis N, Dionyssiou-Asteriou A, Lianidou ES (2006)
Presence of high-risk human papillomavirus sequences in breast cancer tissues
and association with histopathological characteristics. Clin Biochem 39: 727–
731.
4. de Leon DC, Montiel DP, Nemcova J, Mykyskova I, Turcios E, et al. (2009)
Human papillomavirus (HPV) in breast tumors: prevalence in a group of
Mexican patients. BMC Cancer 9: 26.
5. Lawson JS, Gunzburg WH, Whitaker NJ (2006) Viruses and human breast
cancer. Future Microbiol 1: 33–51.
6. Heng B, Glenn WK, Ye Y, Tran B, Delprado W, et al. (2009) Human papilloma
virus is associated with breast cancer. Br J Cancer 101: 1345–1350.
7. Glenn WK, Heng B, Delprado W, Iacopetta B, Whitaker NJ, et al. (2012)
Epstein-Barr virus, human papillomavirus and mouse mammary tumour virus as
multiple viruses in breast cancer. PLoS One 7: e48788.
8. Antonsson A, Spurr TP, Chen AC, Francis GD, McMillan NA, et al. (2011)
High prevalence of human papillomaviruses in fresh frozen breast cancer
samples. J Med Virol 83: 2157–2163.
9. Mammas IN, Sourvinos G, Zaravinos A, Spandidos DA (2011) Vaccination
against human papilloma virus (HPV): epidemiological evidence of HPV in non-
genital cancers. Pathol Oncol Res 17: 103–119.
10. Simoes PW, Medeiros LR, Simoes Pires PD, Edelweiss MI, Rosa DD, et al.
(2012) Prevalence of human papillomavirus in breast cancer: a systematic
review. Int J Gynecol Cancer 22: 343–347.
11. Moody CA, Laimins LA (2010) Human papillomavirus oncoproteins: pathways
to transformation. Nat Rev Cancer 10: 550–560.
12. zur Hausen H (2002) Papillomaviruses and cancer: from basic studies to clinical
application. Nat Rev Cancer 2: 342–350.
13. Durst M, Gissmann L, Ikenberg H, zur Hausen H (1983) A papillomavirus DNA
from a cervical carcinoma and its prevalence in cancer biopsy samples from
different geographic regions. Proc Natl Acad Sci U S A 80: 3812–3815.
14. zur Hausen H (2009) Papillomaviruses in the causation of human cancers - a
brief historical account. Virology 384: 260–265.
15. Munger K, Howley PM (2002) Human papillomavirus immortalization and
transformation functions. Virus Res 89: 213–228.
16. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, et al. (1999)
Human papillomavirus is a necessary cause of invasive cervical cancer
worldwide. J Pathol 189: 12–19.
17. Gage JR, Meyers C, Wettstein FO (1990) The E7 proteins of the nononcogenic
human papillomavirus type 6b (HPV-6b) and of the oncogenic HPV-16 differ in
retinoblastoma protein binding and other properties. J Virol 64: 723–730.
18. Munger K, Werness BA, Dyson N, Phelps WC, Harlow E, et al. (1989) Complex
formation of human papillomavirus E7 proteins with the retinoblastoma tumor
suppressor gene product. EMBO J 8: 4099–4105.
19. Duensing S, Munger K (2004) Mechanisms of genomic instability in human
cancer: insights from studies with human papillomavirus oncoproteins.
Int J Cancer 109: 157–162.
20. MacMicking JD (2012) Interferon-inducible effector mechanisms in cell-
autonomous immunity. Nat Rev Immunol 12: 367–382.
21. Conticello SG (2008) The AID/APOBEC family of nucleic acid mutators.
Genome Biol 9: 229.
22. Holmes RK, Malim MH, Bishop KN (2007) APOBEC-mediated viral
restriction: not simply editing? Trends Biochem Sci 32: 118–128.
23. Wedekind JE, Dance GS, Sowden MP, Smith HC (2003) Messenger RNA
editing in mammals: new members of the APOBEC family seeking roles in the
family business. Trends Genet 19: 207–216.
24. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, et al. (2013)
Signatures of mutational processes in human cancer. Nature 500: 415–421.
25. Burns MB, Lackey L, Carpenter MA, Rathore A, Land AM, et al. (2013)
APOBEC3B is an enzymatic source of mutation in breast cancer. Nature 494:
366–370.
26. Burns MB, Temiz NA, Harris RS (2013) Evidence for APOBEC3B mutagenesis
in multiple human cancers. Nat Genet 45: 977–983.
27. Kuong KJ, Loeb LA (2013) APOBEC3B mutagenesis in cancer. Nat Genet 45:
964–965.
28. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, et al. (2013)
Mutational heterogeneity in cancer and the search for new cancer-associated
genes. Nature 499: 214–218.
29. Matsumoto Y, Marusawa H, Kinoshita K, Endo Y, Kou T, et al. (2007)
Helicobacter pylori infection triggers aberrant expression of activation-induced
cytidine deaminase in gastric epithelium. Nat Med 13: 470–476.
30. Engels K, Jungnickel B, Tobollik S, Hansmann ML, Kriener S, et al. (2008)
Expression of activation-induced cytidine deaminase in malignant lymphomas
infiltrating the bone marrow. Appl Immunohistochem Mol Morphol 16: 521–
529.
31. Klemm L, Duy C, Iacobucci I, Kuchen S, von Levetzow G, et al. (2009) The B
cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic
myeloid leukemia. Cancer Cell 16: 232–245.
32. Chansaenroj J, Theamboonlers A, Chinchai T, Junyangdikul P, Swangvaree S,
et al. (2012) High-risk human papillomavirus genotype detection by electro-
chemical DNA chip method. Asian Pac J Cancer Prev 13: 1151–1158.
33. Mori S, Nakao S, Kukimoto I, Kusumoto-Matsuo R, Kondo K, et al. (2011)
Biased amplification of human papillomavirus DNA in specimens containing
multiple human papillomavirus types by PCR with consensus primers. Cancer
Sci 102: 1223–1227.
34. Allred DC, Brown P, Medina D (2004) The origins of estrogen receptor alpha-
positive and estrogen receptor alpha-negative human breast cancer. Breast
Cancer Res 6: 240–245.
35. Chung SH, Wiedmeyer K, Shai A, Korach KS, Lambert PF (2008)
Requirement for estrogen receptor alpha in a mouse model for human
papillomavirus-associated cervical cancer. Cancer Res 68: 9928–9934.
36. Shai A, Pitot HC, Lambert PF (2008) p53 Loss synergizes with estrogen and
papillomaviral oncogenes to induce cervical and breast cancers. Cancer Res 68:
2622–2631.
37. Duensing S, Munger K (2002) The human papillomavirus type 16 E6 and E7
oncoproteins independently induce numerical and structural chromosome
instability. Cancer Res 62: 7075–7082.
38. Roberts SA, Lawrence MS, Klimczak LJ, Grimm SA, Fargo D, et al. (2013) An
APOBEC cytidine deaminase mutagenesis pattern is widespread in human
cancers. Nat Genet 45: 970–976.
39. Aguayo F, Khan N, Koriyama C, Gonzalez C, Ampuero S, et al. (2011) Human
papillomavirus and Epstein-Barr virus infections in breast cancer from chile.
Infect Agent Cancer 6: 7.
40. Schmitz KM, Petersen-Mahrt SK (2012) AIDing the immune system-DIAbolic
in cancer. Semin Immunol 24: 241–245.
41. Trinchieri G (2012) Cancer and inflammation: an old intuition with rapidly
evolving new concepts. Annu Rev Immunol 30: 677–706.
42. Nik-Zainal S, Alexandrov LB, Wedge DC, Van Loo P, Greenman CD, et al.
(2012) Mutational processes molding the genomes of 21 breast cancers. Cell 149:
979–993.
43. Tanaka Y, Marusawa H, Seno H, Matsumoto Y, Ueda Y, et al. (2006) Anti-viral
protein APOBEC3G is induced by interferon-alpha stimulation in human
hepatocytes. Biochem Biophys Res Commun 341: 314–319.
44. Chiba T, Marusawa H (2009) A novel mechanism for inflammation-associated
carcinogenesis; an important role of activation-induced cytidine deaminase
(AID) in mutation induction. J Mol Med (Berl) 87: 1023–1027.
45. Dedeoglu F, Horwitz B, Chaudhuri J, Alt FW, Geha RS (2004) Induction of
activation-induced cytidine deaminase gene expression by IL-4 and CD40
ligation is dependent on STAT6 and NFkappaB. Int Immunol 16: 395–404.
High-Risk HPV and APOBEC3B in Breast Cancer
PLOS ONE | www.plosone.org 11 May 2014 | Volume 9 | Issue 5 | e97787 Table S1 Primers and Oligonucleotides information. The
information of RT-PCR primers and shRNA sequences used in
present study.
(DOC)
Table S2 HPV genome copy number in BC. HPV16 and 18
viral DNA in breast cancer (BC) and cervical cancer (CC) tissues
were quantified by real-time quantitative polymerase chain
reaction (PCR) using a TaqMan probes as mentioned in. Viral
DNA was calculated based on the standard curve of control DNA.
(DOC)46. Endo Y, Marusawa H, Kinoshita K, Morisawa T, Sakurai T, et al. (2007)
Expression of activation-induced cytidine deaminase in human hepatocytes via
NF-kappaB signaling. Oncogene 26: 5587–5595.
47. Hussain SP, Hofseth LJ, Harris CC (2003) Radical causes of cancer. Nat Rev
Cancer 3: 276–285.
48. Sedelnikova OA, Redon CE, Dickey JS, Nakamura AJ, Georgakilas AG, et al.
(2010) Role of oxidatively induced DNA lesions in human pathogenesis. Mutat
Res 704: 152–159.
49. Chen BP, Li M, Asaithamby A (2012) New insights into the roles of ATM and
DNA-PKcs in the cellular response to oxidative stress. Cancer Lett 327: 103–
110.
50. Handa O, Naito Y, Yoshikawa T (2010) Helicobacter pylori: a ROS-inducing
bacterial species in the stomach. Inflamm Res 59: 997–1003.
51. De Marco F (2013) Oxidative stress and HPV carcinogenesis. Viruses 5: 708–
731.
52. De Marco F, Bucaj E, Foppoli C, Fiorini A, Blarzino C, et al. (2012) Oxidative
stress in HPV-driven viral carcinogenesis: redox proteomics analysis of HPV-16
dysplastic and neoplastic tissues. PLoS One 7: e34366.
53. Williams VM, Filippova M, Soto U, Duerksen-Hughes PJ (2011) HPV-DNA
integration and carcinogenesis: putative roles for inflammation and oxidative
stress. Future Virol 6: 45–57.
High-Risk HPV and APOBEC3B in Breast Cancer
PLOS ONE | www.plosone.org 12 May 2014 | Volume 9 | Issue 5 | e97787